Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective.

Abstract

Tulathromycin is approved in the United States for the treatment of respiratory disease in bovine and swine, infectious bovine keratoconjunctivitis associated with Moraxella bovis, and interdigital necrobacillosis in bovine. This macrolide highly concentrates in lung tissue and persists in the intra-airway compartment for a long time after a single administration. It also accumulates in inflammatory cells, including neutrophils and macrophages. This article reviews pharmacokinetic information about tulathromycin in different veterinary species with particular emphasis on the respiratory system.

• Authors: N Villarino, S A Brown, T Martín-Jiménez
• Journal: Journal of veterinary pharmacology and therapeutics (J Vet Pharmacol Ther) Vol. 37 Issue 3 Pg. 211-21 (Jun 2014) ISSN: 1365-2885 [Electronic] England
• PMID: 24117832 (Publication Type: Journal Article, Review)
• Copyright: © 2013 John Wiley & Sons Ltd.

Chemical References

• Anti-Bacterial Agents
• Disaccharides
• Heterocyclic Compounds
• tulathromycin

Topics

• Animals
• Anti-Bacterial Agents (pharmacokinetics, therapeutic use)
• Disaccharides (pharmacokinetics, therapeutic use)
• Heterocyclic Compounds (pharmacokinetics, therapeutic use)
• Lung Diseases (drug therapy, veterinary)